biosimilars Archives -

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines

Challenges and opportunities in the off-patent sector: the pharmaphorum podcast

https://pharmaphorum.com/r-d/challenges-and-opportunities-in-the-off-patent-sector/

News/ News/ Sales and Marketing

Novartis faces tougher decision on Sandoz, as finances recover

Phil Taylor biosimilars, Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis said this morning that it remains on course to make a decision on the future of its

Novartis faces tougher decision on Sandoz, as finances recover

https://pharmaphorum.com/news/novartis-faces-tougher-decision-on-sandoz-as-finances-recover/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Five things to watch as the Biosimilars market heats up in 2022

mike.hammerton@pharmaphorum.com biosimilars, fda, Janssen 0 Comment

As pressure mounts on the U.S. Congress and the White House to curtail prescription drug prices, many experts

Five things to watch as the Biosimilars market heats up in 2022

https://pharmaphorum.com/market-access-2/five-things-to-watch-as-the-biosimilars-market-heats-up-in-2022/

News/ News/ Sales and Marketing

Deals build Fresenius Kabi’s position in biosimilars, medtech

Phil Taylor Biopharmaceutical, biosimilars, Fresenius Kabi, Ivenix, M&A, mAbxience, medical technology 0 Comment

German injectable medicines specialist Fresenius Kabi has made a pair of deals to kickstart its new strategic direction,

Deals build Fresenius Kabi’s position in biosimilars, medtech

https://pharmaphorum.com/news/deals-build-fresenius-kabis-position-in-biosimilars-medtech/

Market Access/ Views & Analysis/ Views and analysis

Biosimilars: a rapidly maturing market

Ben Hargreaves Association for Accessible Medicine, Bioepis, biologic treatments, biosimilars 0 Comment

Adoption of biosimilars in the US has been notoriously slow, but biosimilars manufacturers and outside observers expect this

Biosimilars: a rapidly maturing market

https://pharmaphorum.com/market-access-2/biosimilars-a-rapidly-maturing-market/

News/ News/ Sales and Marketing

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

Phil Taylor biosimilars, Comirnaty, Eliquis, Financial, Paxlovid, Pfizer, Sales and Marketing, Vyndaqel 0 Comment

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in

Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year

https://pharmaphorum.com/news/pfizers-covid-boom-goes-on-as-it-eyes-22bn-in-paxlovid-sales-this-year/

News/ News/ Sales and Marketing

Biogen exits biosimilar JV with Samsung, raising $2.3bn

Phil Taylor Biogen, biosimilars, M&A, Samsung, Samsung Bioepis 0 Comment

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal

Biogen exits biosimilar JV with Samsung, raising $2.3bn

https://pharmaphorum.com/news/biogen-exits-biosimilar-jv-with-samsung-raising-2-3bn/

Podcast/ Video/ Views and analysis

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

Dominic Tyer biosimilars, Regulatory affairs, Sandoz 0 Comment

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

https://pharmaphorum.com/video/sandozs-pierre-bourdage-biosimilars/

Market Access/ News/ News

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

Richard Staines AbbVie, Alvotech, biosimilars, Humira, inflammatory diseases, patent 0 Comment

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira

Alvotech files lawsuit challenging AbbVie’s Humira patent thicket

https://pharmaphorum.com/news/alvotech-files-lawsuit-challenging-abbvies-humira-patent-thicket/

Trending

biosimilars

Login